worth repeating My compliments to notale, for vwery concise recap of ONCs bio, vs anoher company with much less trading at $2.8 billion.
Im repostng this , as far more important than any drivel, other backgound drivel
Thanks for the hard work notable.
.So let's get back to the facts of the matter. CGON has one indication in late stage clinical trials and has a market cap of US$2.7 Billion.
ONCY has 5 indications that are Phase 2/3 / Accelerated Approval ready.
This is particularly threatenting to those others who are supporting other oncolytic virus companies and who post smack on this message board.
These 5 indications with pelareorep are:
(1) HR+/HER2 negative metastatic breast cancer;
(2) Triple Negative Breast Cancer (TNBC);
(3) pancreatic cancer with pelareorep + ICI + n-paclitaxel;
(4) pancreatic cancer with pelareorep + ICI + folfirinox, and;
(5) anal (SCCA) cancers.
Furthermore, ONCY needs to update its shareholders that pelareorep is effective as a single dose in the treatment of Hepatocellular carcinoma cancer (HCC), as recently demonstrated in an updated paper.
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=34674668
https://www.medrxiv.org/content/10.1101/2024.09.26.24314049v